Description
Zoprotec Film Tablet 15 mg, formulated with the active compound Zofenopril Calcium, is a trusted pharmaceutical agent widely used in the treatment of hypertension and acute myocardial infarction. As an angiotensin-converting enzyme (ACE) inhibitor, Zoprotec contributes significantly to cardiovascular health by reducing blood pressure and enhancing cardiac function in select patient populations. This article offers an in-depth analysis of its pharmacological profile, clinical applications, and safety considerations.
Aspect | Details |
---|---|
Active Ingredient | Zofenopril Calcium |
Composition | Each Zoprotec 15 mg film-coated tablet contains 15 mg of Zofenopril Calcium, equivalent to 14.3 mg of Zofenopril. Excipients include microcrystalline cellulose, lactose monohydrate (sourced from cow’s milk), and others. |
Indications | Zoprotec is an Angiotensin-Converting Enzyme (ACE) inhibitor used for hypertension treatment and in the acute phase of myocardial infarction in hemodynamically stable patients not receiving thrombolytic therapy. |
Dosage and Admin. | Dosage is individualized, taken orally after a meal. |
Zoprotec Dosage
The dosing regimen for Zoprotec is individualized, tailored to the patient’s clinical condition, comorbidities, and response to therapy. It is administered orally, typically following a meal to optimize gastrointestinal absorption.
Initiation of treatment generally begins with a lower dose, followed by gradual titration under medical supervision. Frequent monitoring of blood pressure, renal function, and serum electrolytes is essential during therapy initiation and dose adjustments.
Clinical Benefits
Zoprotec has demonstrated significant clinical benefits in both hypertensive patients and individuals recovering from myocardial infarction. Key advantages include:
- Sustained blood pressure reduction.
- Improvement in left ventricular function post-MI.
- Decreased incidence of heart failure.
- Favorable tolerability profile compared to older ACE inhibitors.
When used in accordance with clinical guidelines, Zoprotec contributes to long-term cardiovascular risk reduction.
Interactions
Healthcare professionals must exercise caution when prescribing Zoprotec concomitantly with certain medications. Notable interactions include:
- Potassium-sparing diuretics and potassium supplements: Risk of hyperkalemia.
- Lithium: Increased serum lithium levels and potential toxicity.
- Anesthetics and narcotics: Enhanced hypotensive effects.
- Antipsychotics: Increased risk of orthostatic hypotension.
Patients should provide a comprehensive list of current medications, including over-the-counter drugs and dietary supplements, to avoid potential adverse interactions.
Contraindications and Cautions
Zoprotec is contraindicated in the following scenarios:
- Known hypersensitivity to Zofenopril Calcium or other ACE inhibitors.
- History of angioedema related to previous ACE inhibitor therapy.
- Severe hepatic impairment.
- Bilateral renal artery stenosis.
- Pregnancy and lactation.
- Conditions associated with elevated risk of angioedema.
Due to the teratogenic potential of ACE inhibitors, Zoprotec must not be used during pregnancy, especially in the second and third trimesters.
Storage Guidelines
To maintain the medication’s stability and efficacy, Zoprotec should be stored at a temperature not exceeding 25°C. The storage area should be dry, well-ventilated, and free from direct light exposure. It is recommended to implement a quarantine zone for expired or damaged tablets, ensuring pharmaceutical integrity and patient safety.
Side Effects
Although generally well-tolerated, Zoprotec may produce adverse effects in some individuals. Common side effects include:
- Cough (dry and persistent)
- Headache
- Dizziness or lightheadedness
- Fatigue
- Gastrointestinal disturbances (nausea, diarrhea)
Rare but serious effects include:
- Angioedema
- Hyperkalemia
- Hepatic dysfunction
- Renal impairment
Routine monitoring of renal parameters and electrolyte levels is advised, especially in elderly patients or those with preexisting kidney conditions.
The Mechanism of Action
Central to Zoprotec’s efficacy is its active ingredient, Zofenopril Calcium. As an ACE inhibitor, it suppresses the plasma renin-angiotensin-aldosterone system, leading to reduced vasopressor activity and aldosterone secretion. This culminates in vasodilation, lowered blood pressure, and enhanced cardiac function. It is crucial to understand that Zofenopril Calcium undergoes metabolism in the body to produce zofenoprilat, the active drug responsible for these effects.
Summary Table: Key Details of Zoprotec Film Tablet 15 mg
Aspect | Details |
---|---|
Active Ingredient | Zofenopril Calcium |
Strength | 15 mg per tablet (equivalent to 14.3 mg Zofenopril) |
Therapeutic Class | ACE Inhibitor |
Indications | Hypertension, acute myocardial infarction |
Dosage Form | Oral film-coated tablet |
Route of Administration | Oral, preferably after meals |
Mechanism of Action | Inhibits ACE, reduces angiotensin II and aldosterone, causes vasodilation |
Contraindications | Hypersensitivity, pregnancy, hepatic impairment, renal artery stenosis, angioedema history |
Interactions | Potassium diuretics, lithium, anesthetics, antipsychotics |
Common Side Effects | Cough, dizziness, fatigue, headache, gastrointestinal upset |
Storage Conditions | Store below 25°C, away from light, in dry conditions |
Packaging | Typically available in blister packs, quantity per pack may vary |
Conclusion
Zoprotec Film Tablet 15 mg, enriched with Zofenopril Calcium, remains a pivotal tool in the management of hypertension and acute myocardial infarction. Its efficacy, coupled with a relatively favorable safety profile, makes it a preferred choice among ACE inhibitors. However, its administration should be overseen by qualified healthcare professionals to ensure personalized dosing, appropriate monitoring, and minimization of adverse effects. In the context of comprehensive cardiovascular care, Zoprotec continues to reinforce its therapeutic relevance and clinical utility.
Reviews
There are no reviews yet.